Total Payments
$1,573
2024 Payments
$285.92
Companies
26
Transactions
93
Medicare Patients
7,288
Medicare Billing
$557,551
Payment Breakdown by Category
Food & Beverage$1,192 (75.8%)
Education$380.05 (24.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,192 | 68 | 75.8% |
| Education | $380.05 | 25 | 24.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $401.54 | 28 | $0 (2024) |
| ARRAY BIOPHARMA INC | $124.66 | 8 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $119.76 | 6 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $118.30 | 7 | $0 (2023) |
| Genentech USA, Inc. | $88.69 | 5 | $0 (2022) |
| Merck Sharp & Dohme LLC | $80.91 | 4 | $0 (2024) |
| Exelixis Inc. | $61.81 | 3 | $0 (2022) |
| Eisai Inc. | $56.64 | 3 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $53.36 | 3 | $0 (2018) |
| ABBVIE INC. | $48.88 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $285.92 | 15 | E.R. Squibb & Sons, L.L.C. ($81.07) |
| 2023 | $465.66 | 30 | PFIZER INC. ($178.89) |
| 2022 | $516.80 | 29 | PFIZER INC. ($146.49) |
| 2021 | $80.82 | 5 | Ipsen Biopharmaceuticals, Inc ($23.42) |
| 2019 | $38.93 | 3 | PFIZER INC. ($13.35) |
| 2018 | $103.46 | 6 | Genentech USA, Inc. ($40.55) |
| 2017 | $80.94 | 5 | Exelixis Inc. ($35.32) |
All Payment Transactions
93 individual payment records from CMS Open Payments — Page 4 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/22/2021 | Amgen Inc. | LUMAKRAS (Drug) | Food and Beverage | In-kind items and services | $12.87 | General |
| Category: Oncology | ||||||
| 10/19/2021 | Ipsen Biopharmaceuticals, Inc | SOMATULINE DEPOT (Drug), ONIVYDE | Food and Beverage | In-kind items and services | $23.42 | General |
| Category: Oncology/Endocrinology | ||||||
| 07/01/2021 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug), RYDAPT | Food and Beverage | In-kind items and services | $14.56 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 12/19/2019 | Rigel Pharmaceuticals, Inc. | Tavalisse (Drug) | Food and Beverage | In-kind items and services | $13.31 | General |
| Category: Hematology | ||||||
| 03/06/2019 | PFIZER INC. | SUTENT (Drug), INLYTA, BAVENCIO | Food and Beverage | In-kind items and services | $13.35 | General |
| Category: ONCOLOGY;RESPIRATORY | ||||||
| 02/26/2019 | Genentech USA, Inc. | VENCLEXTA (Biological) | Food and Beverage | In-kind items and services | $12.27 | General |
| Category: BioOncology | ||||||
| 11/09/2018 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $12.45 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2018 | Genentech USA, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $22.88 | General |
| Category: BioOncology | ||||||
| 09/20/2018 | Genentech USA, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $17.67 | General |
| Category: BioOncology | ||||||
| 09/04/2018 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $17.54 | General |
| Category: Oncology | ||||||
| 08/21/2018 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $16.36 | General |
| Category: ONCOLOGY | ||||||
| 03/15/2018 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $16.56 | General |
| Category: Oncology | ||||||
| 11/14/2017 | PFIZER INC. | MYLOTARG (Drug), BOSULIF, IBRANCE | Food and Beverage | In-kind items and services | $13.64 | General |
| Category: ONCOLOGY | ||||||
| 10/03/2017 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $19.26 | General |
| Category: Oncology | ||||||
| 07/25/2017 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $12.72 | General |
| Category: ONCOLOGY | ||||||
| 06/20/2017 | Exelixis Inc. | Cabometyx (Drug) | Education | In-kind items and services | $17.66 | General |
| Category: Oncology | ||||||
| 04/26/2017 | Exelixis Inc. | Cabometyx (Drug) | Education | In-kind items and services | $17.66 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 1,671 | 4,434 | $326,645 | $143,606 |
| 2022 | 10 | 1,886 | 4,697 | $352,299 | $145,734 |
| 2021 | 10 | 1,794 | 4,374 | $316,984 | $141,340 |
| 2020 | 11 | 1,937 | 4,799 | $317,914 | $126,871 |
Total Patients
7,288
Total Services
18,304
Medicare Billing
$557,551
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 310 | 818 | $150,512 | $71,143 | 47.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 322 | 564 | $72,756 | $33,244 | 45.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 464 | 1,509 | $19,538 | $12,587 | 64.4% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 444 | 1,348 | $49,876 | $10,203 | 20.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 35 | 89 | $10,413 | $5,343 | 51.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 38 | 38 | $9,880 | $4,554 | 46.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 26 | 26 | $8,606 | $4,179 | 48.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 11 | 12 | $2,664 | $1,203 | 45.2% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 21 | 30 | $2,400 | $1,148 | 47.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 382 | 881 | $162,104 | $77,214 | 47.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 330 | 609 | $78,561 | $34,700 | 44.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 511 | 1,460 | $54,020 | $11,133 | 20.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 39 | 99 | $11,583 | $5,197 | 44.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 514 | 1,532 | $18,384 | $4,515 | 24.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 28 | 28 | $9,268 | $4,409 | 47.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 31 | 31 | $8,060 | $3,575 | 44.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 23 | 26 | $6,682 | $3,490 | 52.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 12 | 13 | $2,197 | $967.05 | 44.0% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 16 | 18 | $1,440 | $534.30 | 37.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 330 | 753 | $131,788 | $68,809 | 52.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 339 | 625 | $75,452 | $37,327 | 49.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 477 | 1,315 | $48,655 | $10,185 | 20.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 47 | 130 | $15,036 | $7,263 | 48.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 50 | 50 | $12,862 | $5,968 | 46.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 489 | 1,416 | $16,992 | $4,239 | 24.9% |
About Dr. Michael Keefer, M.D
Dr. Michael Keefer, M.D is a Hematology & Oncology healthcare provider based in Oklahoma City, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1386697548.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Keefer, M.D has received a total of $1,573 in payments from pharmaceutical and medical device companies, with $285.92 received in 2024. These payments were reported across 93 transactions from 26 companies. The most common payment nature is "Food and Beverage" ($1,192).
As a Medicare-enrolled provider, Keefer has provided services to 7,288 Medicare beneficiaries, totaling 18,304 services with total Medicare billing of $557,551. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Oklahoma City, OK
- Active Since 05/18/2006
- Last Updated 03/01/2018
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1386697548
Products in Payments
- IBRANCE (Drug) $309.50
- OPDIVO (Biological) $119.76
- KEYTRUDA (Biological) $80.91
- BRAFTOVI (Drug) $65.78
- Cabometyx (Drug) $61.81
- XALKORI (Drug) $58.88
- PADCEV (Biological) $56.96
- Lenvima (Drug) $56.64
- PROMACTA (Drug) $53.92
- Imbruvica (Drug) $53.36
- VENCLEXTA (Drug) $48.88
- TECENTRIQ (Biological) $40.55
- VENCLEXTA (Biological) $35.86
- SIR-Spheres Microspheres (Device) $33.73
- REBLOZYL (Biological) $30.77
- LUMAKRAS (Drug) $29.32
- SARCLISA (Biological) $28.98
- BELEODAQ (Drug) $25.90
- XTANDI (Drug) $24.83
- ORGOVYX (Drug) $24.36
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Oklahoma City
Robert Reynolds, Md, MD
Hematology & Oncology — Payments: $14,579
Hematology & Oncology $14,579
Philip Comp, Md, MD
Hematology & Oncology — Payments: $13,151
Hematology & Oncology $13,151
Dr. Charles Hollen, M.d, M.D
Hematology & Oncology — Payments: $12,135
Hematology & Oncology $12,135
Jennifer Holter-Chakrabarty, Md, MD
Hematology & Oncology — Payments: $11,994
Hematology & Oncology $11,994
Dr. Saadia Chohan, Md, MD
Hematology & Oncology — Payments: $11,197
Hematology & Oncology $11,197
Abby Bova, Md, MD
Hematology & Oncology — Payments: $5,791
Hematology & Oncology $5,791